Charlotte Davison, Board Observer at
“Absolutely thrilled to share that Myricx Bio has joined the British Patient Capital portfolio. We are delighted to have participated in this £90m Series A funding to accelerate development of their novel NMTi ADC platform towards clinic.
It’s been a pleaseure to work with Novo Holdings, Abingworth, Eli Lilly and Company, Sofinnova Partners and Brandon Capital along with a stellar team (Robin Carr, Julie Mead, Francesca Zammarchi) to pull this round together.
Congratulations all! ”